TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06220864: SNV1521 in Participants With Advanced Solid Tumors

Sponsor: ParVation Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$6,314,616

Rescue Site Savings

+$4,178,328

Unlock Full NCT06220864 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06220864 Rescue Dossier →